Topics:

Oncology and Hematology News and Journal Articles

FDA Approves Ramucirumab for Second-Line Treatment of mCRC

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

Recent Content

This slide show features some of the top highlights from the 2015 American Association for Cancer Research (AACR) Annual Meeting.

A 30-year-old man who recently underwent induction chemotherapy for bone marrow transplant is admitted with neutropenia and right lower-quadrant abdominal pain. What is your diagnosis?

Understanding treatment-induced neurotoxicity can be difficult when treating patients with central nervous system (CNS) malignancies.

A multi-gene panel test provides better diagnostic yield compared with a limited BRCA1/2 genetic test for patients at risk for hereditary breast cancer.

The FDA has approved ramucirumab, a human VEGFR2 antagonist in combination with FOLFIRI for second-line treatment of patients with metastatic colorectal cancer.

MM-302 showed encouraging efficacy results and a manageable safety profile in heavily pretreated HER2-positive metastatic breast cancer patients.

This session at ONS reviewed treatment options for CLL and the issues associated with bone marrow transplantation in eligible patients.

By clicking Accept, you agree to become a member of the UBM Medica Community.